tbuckley/cabot-search huggingface dataset:
SAT0085 Relationship between serum calprotectin, disease activity parameters and the 7-joint ultrasound score in rheumatoid arthritis
Authors: M. Torgutalp, A.B. Kelesoglu Dincer, E.M. Yayla, E. Uslu Yurteri, E.I. Okatan, G.E. Aydemir Guloksuz, S. Serdar, U. Ebru, G. Kinikli, M.T. Turgay, A. Ates
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Calprotectin may be a sensitive biomarker of rheumatoid arthritis (RA) disease activity. <h3>Objectives</h3> In this study we aimed to investigate whether calprotectin is a better biomarker than known inflammation markers forpredicting clinical activity and ultrasound parameters in patients with RA. <h3>Methods</h3> A total of 80 RA patients were underwent to clinical (swollen joint count, tender jointcount, disease activity score-DAS28, simplified disease activity index-SDAI and clinical disease activity index-CDAI) and ultrasound (German US7) examination. Correlation ofclinical, laboratory and ultrasound measures wereanalyzed using Spearman'scorrelation coefficient.The RA patients were divided into two subgroups according to their DAS28-ESR (erythrocyte sedimentation rate) score; group 1 (DAS-28 ≤3.2 remission and low activity), group 2 (DAS28 &gt;3.2 moderate and high activity), respectively. Thirty healthy controls were simultaneously studied. <h3>Results</h3> The serum calprotectin levels of the RA patients were significantly higher than those of healthy controls (96.3±45.9, 54.7±50.0, respectively; p&lt;0.001). Distribution of age (years; 57.2±9.6, 53.9±10.5, respectively; p=0.115) and sex (female; 78.8%, 70%, respectively, p=0.336) between these groups were similar.The clinical, laboratory and ultrasound characteristics of the patients are shown in table 1. The calprotectin levels were 74.8±45.5 in group 1 (n=37) and 114.7±37.9 in group 2 (n=43) (p&lt;0.001).The association between calprotectin and scores of DAS28-ESR are shown in figure 1A. Serum calprotectin was significantly associated with DAS28-ESR, DAS28-CRP (C-reactive protein), SDAI, CDAI, ESR, CRP and US7 parameters. We also found a moderate to strong correlation of US7 score with DAS28-ESR, DAS28-CRP, SDAI,CDAI, CRP and ESR (table 2).The correlation between calprotectin and US7 is shown in figure 1B. <h3>Conclusions</h3> The results of our study support an additional role of calprotectin in assessing inflammatory activity in patients with RA.Therefore, the combination of serum calprotectinl evels and the US7 score could be a simple and practical assessment approach for detection of RA disease activity. <h3>Disclosure of Interest</h3> None declared
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Authors: Jean-Michel Molina, Douglas Ward, Indira Brar, Anthony Mills, Hans-Jürgen Stellbrink, Luis López-Cortés, Peter Ruane, Daniel Podzamczer, Cynthia Brinson, Joseph Custodio, Hui Liu, Kristen Andreatta, Hal Martin, Andrew Cheng, Erin Quirk
Journal: The Lancet HIV (2018)
Acute and chronic deterioration in liver function after transarterial radioembolization (TARE) in US patients (pts) with hepatocellular carcinoma (HCC).
Authors: Rebecca A. Miksad, Fabio Piscaglia, Fang Xia, Marc Mardoche Fellous, Sadahisa Ogasawara
Journal: Journal of Clinical Oncology (2018)

439 Background: TARE is available in several countries for the treatment of hepatic malignancies, including unresectable HCC. Liver function deterioration in pts treated with TARE has been reported in real-world practice but less is known about incidence at a national US level. To better understand the prevalence of liver function deterioration after TARE, a retrospective analysis was performed using a database of US HCC pts. Methods: HCC pts treated with index TARE between Jan 1, 2010 and Dec 31, 2015 were identified in Optum’s integrated database using standard codes. Eligible pts had at least one laboratory (lab) value at baseline ( &lt; 30 days before TARE), acute period ( &lt; 30 days post TARE), and chronic period (90–180 days post TARE) and did not undergo additional/repeat HCC treatment before any further lab test in the chronic period. Due to lack of universally accepted criteria for liver function deterioration, clinically meaningful lab parameter changes were predefined by experts (Table). Changes in liver function from baseline were assessed in the acute and chronic periods. Results: Of 790 Optum TARE pts, 78 (10%) were eligible. Majority of pts were excluded due to lack of lab data and due to additional HCC treatments prior to lab tests in the chronic period. 50 (64%) were male and median age was 66 yrs. At baseline, 20 pts (26%) had extrahepatic spread (EHS). The incidence of liver function deterioration varied by parameter (Table). Albumin was the parameter most likely to be changed in both the acute and chronic periods. Conclusions: Although anti-tumor effects are thought to be optimized about 3 months after TARE, this retrospective, post-hoc, real-world analysis demonstrated decreased liver function 90–180 days after TARE. TARE, a liver-directed therapy, was used in some pts with EHS. Limitations include missing data, small sample size, and difficulty establishing causation. These results suggest that chronic liver function deterioration 90–180 days after TARE may be observed in some HCC pts. [Table: see text]
Myocardial Edema and Prognosis in Amyloidosis
Authors: Tushar Kotecha, Ana Martinez-Naharro, Thomas A. Treibel, Rohin Francis, Sabrina Nordin, Amna Abdel-Gadir, Daniel S. Knight, Giulia Zumbo, Stefania Rosmini, Viviana Maestrini, Heerajnarain Bulluck, Roby D. Rakhit, Ashutosh D. Wechalekar, Janet Gilbertson, Mary N. Sheppard, Peter Kellman, Julian D. Gillmore, James C. Moon, Philip N. Hawkins, Marianna Fontana
Journal: Journal of the American College of Cardiology (2018)
Reply to C. Ren et al
Authors: Glenn Heller, Robert McCormack, Thian Kheoh, Arturo Molina, Matthew R. Smith, Robert Dreicer, Fred Saad, Ronald de Wit, Dana T. Aftab, Mohammed Hirmand, Ana Limon-Carrera, Karim Fizazi, Martin Fleisher, Johann S. de Bono, Howard I. Scher
Journal: Journal of Clinical Oncology (2018)
SAT0071 Subchondral osteopenia but not cartilage damage is prevalent in knee joints of prematurely ageing mitochondrial dna mutator mice
Authors: J. Geurts, S. Nasi, T.A. Prolla, G.C. Kujoth, U.A. Walker, T. Hügle
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Mitochondrial dysfunction has been demonstrated in ageing and osteoarthritic tissues. However it remains unclear whether dysfunctional mitochondria are directly implied in the pathogenesis of osteoarthritis. <h3>Objectives</h3> We investigated knee joints of prematurely ageing mitochondrial DNA mutator mice (<i>Polg<sup>D275A</sup></i>) to evaluate a causal relationship between mitochondrial dysfunction and different features of osteoarthritis. <h3>Methods</h3> Bone structural parameters and chondropathy were evaluated in knee joints of mice displaying increased mtDNA mutations rates and accelerated ageing, due to expression of a proofreading-deficient mtDNA polymerase, using micro-computed tomography and histopathological analysis. <h3>Results</h3> Homozygous mutants displayed osteopenia of the epiphyseal trabecular bone and subchondral cortical plate in comparison to wild type controls and heterozygous mutants. Osteopenia was associated with a strong increase of osteoclast numbers (0.88±0.30/mm bone perimeter) compared to heterozygous (0.25±0.03/mm) and wild type mice (0.12±0.04/mm). New bone formation was not observed. Wild type mice displayed only low grade cartilage degeneration (OARSI grade ≤1) due to loss of cartilage proteoglycans. Increased tibio-femoral chondropathy was not apparent in hetero- and homozygous mitochondrial DNA mutator mice. <h3>Conclusions</h3> Mitochondrial dysfunction and premature ageing in mice with somatically acquired mtDNA mutations predisposes to enhanced subchondral bone resorption as potential early step of osteoarthritis, but not to cartilage damage or new bone formation. This phenotype potentially corresponds to an osteoporotic osteoarthritis phenotype in humans. <h3>Disclosure of Interest</h3> None declared
Genetic evidence of Zika virus in mother's breast milk and body fluids of a newborn with severe congenital defects
Authors: M. Giovanetti, J. Goes de Jesus, M. Lima de Maia, J.X. Junior, M.F. Castro Amarante, P. Viana, F. Khouri Barreto, E.M. de Cerqueira, N. Pedreira Santos, M. Barreto Falcão, M.C. Machado Costa, A.V. Barros Faiçal, A.L. Andrade de Melo, L. Santos Amorim, I.C. de Siqueira, D.L. Macarenhas, A.M. Bispo de Filippis, N. Rodrigues Faria, A. Xavier Acosta, L.C. Júnior Alcântara
Journal: Clinical Microbiology and Infection (2018)
THU0506 Cross-sectional analysis of the associations between fibromyalgia and cancer
Authors: A. Lichtenstein, S. Tiosano, D. Comaneshter, A.D. Cohen, H. Amital
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Fibromyalgia syndrome (FMS) is defined as chronic widespread musculoskeletal pain and tenderness with concomitant mood and cognitive dysfunction. Several comorbidities have been reported to be associated with FMS. However, these studies are mostly based on small populations and lack solid evidence. <h3>Objectives</h3> To evaluate the association of FMS with Cancer diagnoses. <h3>Methods</h3> This cross-sectional study used the database of the largest Health Maintenance Organisation in Israel, Clalit Health Services, serving more than 4 million members. FMS patients were compared to age- and sex-matched controls regarding comorbid Cancer diagnoses. Chi-square and t-tests were used for univariate analysis,. <h3>Results</h3> Our study utilised data from 14,296 FMS patients and 71 324 age- and sex-matched controls. FMS patients compared to controls had a higher proportion of the following types of cancer: Cervix and Uteri, Connective Tissue Sarcoma, Thyroid, Non Hodgkin Lymphoma (NHL) and Benign brain tumours (OR=1.39, 1.60, 1.68, 1.26, 1.87 respectively, P value&lt;0.005) – See table 1. <h3>Conclusions</h3> Study results show a higher proportion of malignancy diagnoses amongst FMS patients compared to matched controls. Accordingly, in treating FMS patients, physicians should bear in mind the likelihood of concomitant tumour as it might explain various FMS symptoms, and more importantly, shorten a patients' time for diagnosis and treatment of the oncological condition. <h3>Disclosure of Interest</h3> None declared
THU0208 Effectiveness and safety of certolizumab pegol in rheumatoid arthritispatients after failure to antitnf or naÏve patients in real world setting. one year follow-up experience
Authors: M. Fernández Prada, V. Torrente-Segarra, R. Expósito Molinero, N.P. Garrido Puñal, A. Sánchez-Andrade Fernández, J.R. Lamúa, A. Olivé, J.V. Tovar
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Between 30%–40% of patients with rheumatoid arthritis (RA) discontinue at their first line biological therapy due to inadequate response or adverse events. There is currently a great controversy about using a second anti-TNF, after failure to the first one, or a therapeutic target change, due to the availability of a wide pharmacological arsenal for patients with RA. <h3>Objectives</h3> The objective of this study is to determine the effectiveness and safety during one year of Certolizumab pegol (CZP) in patients with RA in second line (after failed to a previous antiTNF) and compare it with those who received this therapy as first line (bio-naïve). <h3>Methods</h3> National, observational, prospective, longitudinal and multicenter study in patients with RA who received CZP as the first line of biological treatment or failure to a previous anti-TNF for lack of efficacy, during one year of follow-up. Demographic and clinical variables were collected (gender, age, disease duration, TJC, SJC, ESR, CRP, DAS28, HAQ), at baseline visit, 3 and 12 months of treatment. As response variables, DAS28 remission, low disease activity by DAS28 (LDA) and EULAR response, were used. The Student t test and the Mann-Whitney U test were used for the statistical analysis and a survival analysis (Kaplan-Meier) was performed <h3>Results</h3> A total of 360 patients were included, of which 272 (75.6%) were bio-naïve and 88 (24.4%) previous anti-TNF failure. Baseline characteristics of both groups are shown in table 1. Clinical variables of effectiveness at 3 and 12 months are summarised in table 2. Statistically significant differences in DAS28, HAQ and% patients with corticosteroids were observed in both groups at year of treatment comparing with baseline, even though bio-naïve group had a statistically lower DAS28 and a higher percentage response than the antiTNF failure group. According to Kaplan-Meier analysis, similar retention rates were observed independently if CZP were used as first (77.2%) or second line (73.9%). No differences were found in terms of safety at one year of treatment between both groups. <h3>Conclusions</h3> This study, derived from the experience of national clinical practice with CZP, demonstrates the effectiveness and safety of this drug in patients with RA regardless of its use in the first line or after failure to a previous antiTNF, with better response scores in bio-naïve patients. No differences were observed in the retention rate in both groups. <h3>Disclosure of Interest</h3> None declared
AB0520 Assessment of anti- müllerian hormone levels in systemic lupus erythematosus treated with immunosuppressor
Authors: J. Yu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a chronic immune-mediated inflammatory disease that affects predominantly females during childbearing age. Fertility in SLE patients is considered to be normal but several factors, such as disease activity, renal involvement and treatment with immunosuppressor may negatively influence fertility. <h3>Objectives</h3> To investigate the ovarian reserve of patients with SLE by measuring anti-müllerian hormone (AMH) levels, and compare the AMH levels before and after treatment with immunosuppressor. <h3>Methods</h3> This was a self-control study performed on newly diagnosed premenopausal female SLE patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Serum concentrations of AMH in peripheral venous blood were measured using a human AMH ELISA kit (MSKBIO, Wuhan, China) before and after treatment with 6 month immunosuppressor. <h3>Results</h3> 45 patients were recruited. AMH serum levels reduced after treatment in the cyclophosphamide (CTX) group (n=6) and leflunomide (LEF) group (n=7), P&lt;0.05. AMH serum levels did not differ before and after treatment in the mycophenolate (MMF) group (n=11), tacrolimus group (n=8) and methotrexate (MTX) combined with cyclosporin A (CsA) group (n=13), p≥0.05. <h3>Conclusions</h3> In this self-control study, the AMH serum levels reduced after 6 month treatment of CTX or LEF, indicating CTX and LEF might negatively influence ovarian reserve function. AMH serum levels did not differ after 6 month treatment of MMF, tacrolimus or combined use of MTX and CsA, indicating these immunosuppressor might be relatively safe for ovarian reserve function. <h3>References</h3> [1] Lateef A, Petri M. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol. 2013;27(3):435–47. [2] Oktem O, Guzel Y, Aksoy S, et al. Ovarian function and reproductive outcomes of female patients with systemic lupus erythematosus and the strategies to preserve their fertility. Obstet Gynecol Surv2015;70(3):196–210. [3] Martins NFE, Seixas MI, Pereira JP, et al. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus. Clin Rheumatol2017;36(12):2853–2854. [4] Gasparin AA, Souza L, Siebert M, et al. Assessment of anti-Müllerian hormone levels in premenopausal patients with systemic lupus erythematosus. Lupus2016;25(3):227–32. <h3>Disclosure of Interest</h3> J. Yu Grant/research support from: This project was supported by a grant from the Health and Family Planning Commission of Shenzhen Municipality (201601037) and a grant from the Traditional Chinese Medicine Bureau of Guangdong Province (20161228).
Abstract 15792: Reprogramming of Fibroblasts Into Induced Cardiac Progenitor Cells With the CRISPR-dCas9 System
Authors: Lin Jiang, Jialiang Liang, Wei Huang, Wenfeng Cai, Christian Paul, Yigang Wang
Journal: Circulation (2016)

Background and Objective: Currently available regenerative clinical therapies for myocardial infarction could benefit from additional resources of cardiac lineage cells. Although the CRISPR-dCas9 s...
Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells
Authors: Janet Lei, Egon J. Jacobus, William K. Taverner, Kerry D. Fisher, Silvio Hemmi, Katy West, Lorna Slater, Fred Lilley, Alice Brown, Brian Champion, Margaret R. Duffy, Len W. Seymour
Journal: Journal for ImmunoTherapy of Cancer (2018)

<h3>Background</h3> Oncolytic viruses are currently experiencing accelerated development in several laboratories worldwide, with some forty-seven clinical trials currently recruiting. Many oncolytic viruses combine targeted cytotoxicity to cancer cells with a proinflammatory cell lysis. Due to their additional potential to express immunomodulatory transgenes, they are also often known as oncolytic viral vaccines. However, several types of oncolytic viruses are human-specific and the lack of suitable immune-competent animal models complicates biologically relevant evaluation of their vaccine potential. This is a particular challenge for group B adenoviruses, which fail to infect even those immunocompetent animal model systems identified as semi-permissive for type 5 adenovirus. Here, we aim to develop a murine cell line capable of supporting replication of a group B oncolytic adenovirus, enadenotucirev (EnAd), for incorporation into a syngeneic immunocompetent animal model to explore the oncolytic vaccine potential of group B oncolytic viruses. <h3>Methods</h3> Transgenic murine cell lines were infected with EnAd expressing GFP transgene under replication-independent or -dependent promoters. Virus mRNA expression, genome replication, and late protein expression were determined by qRT-PCR, qPCR, and immunoblotting, respectively. We also use Balb/c immune-competent mice to determine the tumourogenicity and infectivity of transgenic murine cell lines. <h3>Results</h3> Our results show that a broad range of human carcinoma cells will support EnAd replication, but not murine carcinoma cells. Murine cells can be readily modified to express surface human CD46, one of the receptors for group B adenoviruses, allowing receptor-mediated uptake of EnAd particles into the murine cells and expression of CMV promoter-driven transgenes. Although the early E1A mRNA was expressed in murine cells at levels similar to human cells, adenovirus E2B and Fibre mRNA expression levels were hampered and few virus genomes were produced. Unlike previous reports on group C adenoviruses, trans-complementation of group B adenoviruses by co-infection with mouse adenovirus 1 did not rescue replication. A panel of group B adenoviruses expressing individual mouse adenovirus 1 genes were also unable to rescue EnAd replication. <h3>Conclusion</h3> Together, these results indicate that there may be major differences in the early stages of replication of group C and B adenoviruses in murine cells, and that the block to the life cycle of B adenoviruses in murine cells occurs in the early stage of virus replication, perhaps reflecting poor activity of Ad11p E1A in murine cells.
OP0188 Effects of allopurinol versus febuxostat on cardiovascular risk in korean patients with gout: a nation-wide cohort study
Authors: A. Shin, M.H. Kim, Y.-J. Ha, Y.J. Lee, Y. Song, S.C. Kim, E.H. Kang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Gout is associated with an increased risk of cardiovascular (CV) disease. <h3>Objectives</h3> We aimed to investigate comparative CV risk among gout patients who initiated allopurinol versus febuxostat. <h3>Methods</h3> Using the 2002–2015 Korean National Health Insurance Service (KNHIS) data for the whole Korean population, we conducted a cohort study on patients aged ≥40 years who had ICD-10 diagnosis code for gout and initiated allopurinol or febuxostat without prior history of urate lowering therapy, excluding those with chronic kidney disease, cancer, or dialysis treatment. The primary outcome was a composite CV endpoint of hospitalisation for myocardial infarction, stroke/transient ischaemic attack, or coronary revascularisation. Secondary outcomes were individual components of the primary outcome, and hospitalisation for heart failure (HF). Follow-up time started from the day after the first date the study drug was initiated and continued through to the earliest date among the following censoring events: discontinuation of the study drugs, outcome occurrence, disenrollment, end of study dataset, or death. After propensity score (PS)-matching with a 4:1 ratio for allopurinol and febuxostat initiators to adjust for baseline confounding, we estimated hazard ratio (HR) and 95% confidence interval (CI) of CV risks in allopurinol initiators versus febuxostat. <h3>Results</h3> We included 39 636 allopurinol initiators PS-matched on 9909 febuxostat initiators with a mean age of 59 years and 78% male. Before PS matching, baseline CV risk factors including hypertension, dyslipidemia, diabetes, and previous ischaemic heart disease were more prevalent in febuxostat initiators. The incidence rate per 100 person-years for primary composite endpoint was 2.33 in allopurinol and 2.12 in febuxostat initiators in the primary as-treated analysis. The HR (95% CI) for the primary outcome associated with allopurinol was 1.18 (0.98–1.42) versus febuxostat. Secondary outcome analyses showed similar results (table 1). Propensity-score matching was used to adjust more than 50 covariates including demographic characteristics, medical comorbidities such as CV risk factors, use of gout specific and non-specific medications, and health care utilisation pattern. CI=confidence interval; CV=cardiovascular; HR=hazard ratio; MI=myocardial infarction; TIA=transient ischaemic attack <h3>Conclusions</h3> In this large Korean population-based cohort study, CV risks appear to be numerically, but not statistically significantly, elevated among allopurinol initiators compared to febuxostat initiators. <h3>Disclosure of Interest</h3> None declared
Substitute Decision Making in End-of-Life Care
Authors: Lisa Caulley, Muriel R. Gillick, Lisa S. Lehmann
Journal: New England Journal of Medicine (2018)

This interactive feature about end-of-life decisions for patients who do not have decision-making capacity or an advance directive offers a case vignette accompanied by essays that support either instituting a do-not-resuscitate order or continuing full resuscitation measures.